Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL27735935 | 0.87 | ALDH1A1 (0.47) | ALDH1A1CXCR4SMN1; SMN2MAPT | |
| Piperazine SCHEMBL27628485 | 0.85 | HIF1A (0.50) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperazine SCHEMBL3937304 | 0.85 | HIF1A (0.50) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Pyrrolidine SCHEMBL23354581 | 0.79 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Pyrrolidine SCHEMBL29601650 | 0.79 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Pyrrolidine SCHEMBL28575035 | 0.79 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL6275420 | 0.77 | — | — | |
| Pyrrolidine SCHEMBL28409763 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL1242732 | 0.76 | ALDH1A1 (0.60) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL9857707 | 0.76 | ALDH1A1 (0.60) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906246-B1 | VEGF NEUTRALIZING PRODRUGS COMPRISING RANIBIZUMAB FOR THE TREATMENT OF OCULAR CONDITIONS CHARACTERIZED BY OCULAR NEOVASCULARIZATION | ASCENDIS PHARMA OPHTHALMOLOGY DIV A/S (DK) | 2023-07-26 | — | — | EP | disclosed |
| EP-3054981-B1 | PROTECTING GROUP COMPRISING A PURIFICATION TAG | ASCENDIS PHARMA AS (DK) | 2020-07-29 | — | — | EP | disclosed |
| US-20180312582-A1 | Protecting Group Comprising a Purification Tag | ASCENDIS PHARMA A/S (DK) | 2018-11-01 | — | — | US | disclosed |
| US-10040850-B2 | Protecting group comprising a purification tag | ASCENDIS PHARMA A/S (DK) | 2018-08-07 | — | — | US | disclosed |
| US-20160257739-A1 | PROTECTING GROUP COMPRISING A PURIFICATION TAG | ASCENDIS PHARMA A/S (DK) | 2016-09-08 | — | — | US | disclosed |
| EP-3054981-A1 | PROTECTING GROUP COMPRISING A PURIFICATION TAG | Ascendis Pharma A/S (DK) | 2016-08-17 | — | — | EP | disclosed |
| US-20150297740-A1 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions | ASCENDIS PHARMA INC. | 2015-10-22 | — | — | US | disclosed |
| EP-2906246-A1 | VEGF NEUTRALIZING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthalmology Division A/S (DK) | 2015-08-19 | — | — | EP | disclosed |
| WO-2015052155-A1 | PROTECTING GROUP COMPRISING A PURIFICATION TAG | ASCENDIS PHARMA A/S (DK) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257739-A1 | PROTECTING GROUP COMPRISING A PURIFICATION TAG | GSTA2, GSTP1, MLN | ALDH1A1 853/4885CXCR4 2399/4885SMN1; SMN2 3592/4885 |
| US-10040850-B2 | Protecting group comprising a purification tag | GSTA2, GSTP1, MLN | ALDH1A1 853/4885CXCR4 2399/4885SMN1; SMN2 3592/4885 |
| US-20180312582-A1 | Protecting Group Comprising a Purification Tag | GSTA2, GSTP1, MLN | ALDH1A1 853/4885CXCR4 2399/4885SMN1; SMN2 3592/4885 |
| US-20150297740-A1 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions | VEGFA, KDR, FLT1 | ALDH1A1 805/4885CXCR4 105/4885SMN1; SMN2 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.